Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
Satellos Bioscience Inc. (MSLE)
Company Research
Source: Business Wire
TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will present two oral scientific presentations and three posters at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, taking place March 8-11 in Orlando, Florida.Oral presentations feature data from the completed Phase 1a/b study of SAT-3247 in healthy volunteers and adult patients with Duchenne muscular dystrophy (DMD), as well as new preclinical data evaluating the impact of SAT-3247 in a mouse model of facioscapulohumeral muscular dystrophy (FSHD).Oral Presentations:Abstract Title: Assessing the impact of SAT-3247 on muscle force in a mouse model of FSHDPresenter: Phil Lambert, PhD, Satellos Chief Scientific OfficerTime: Wednesday, Mar. 11, 9:30 – 9:45 a.m. ETSession: Novel Therapeutics ApproachesLocation:
Show less
Read more
Impact Snapshot
Event Time:
MSLE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MSLE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MSLE alerts
High impacting Satellos Bioscience Inc. news events
Weekly update
A roundup of the hottest topics
MSLE
News
- Satellos Bioscience (MSLE) is now covered by Guggenheim. They set a "buy" rating and a $23.00 price target on the stock.MarketBeat
- Satellos Bioscience (MSLE) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=MSLE&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "seMarketBeat
- Satellos to Present at the Bloom Burton & Co. Healthcare Investor ConferenceGlobeNewswire
- Satellos Bioscience (MSLE) is now covered by Leerink Partners. They set an "outperform" rating and a $20.00 price target on the stock.MarketBeat
- Satellos Bioscience (MSLE) had its price target raised by HC Wainwright from $1.20 to $11.00. They now have a "buy" rating on the stock.MarketBeat
MSLE
Sec Filings
- 4/9/26 - Form 6-K
- 3/27/26 - Form S-8
- 3/27/26 - Form 40-F
- MSLE's page on the SEC website